The levels of pro-inflammatory markers, such as IL-6, IL-1β, and TNF-α, were significantly reduced after EA administration, confirming the compound's ability to mitigate hepatic steatosis and inflammation in a dose-responsive manner (Fig. 2I–K). This evidence concerns the gene IL6 and fatty liver disease.